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Abstract
Background: The CCR5 receptor, expressed on Th1 cells, may influence clinical outcomes of HCV infection. We explored a
possible link between a CCR5 32-base deletion (CCR5delta32), resulting in the expression of a non-functioning receptor, and
clinical outcomes of HCV infection.
Methods: CCR5 and HCV-related phenotypes were analysed in 1,290 chronically infected patients and 160 patients with
spontaneous clearance.
Results: Carriage of the CCR5delta32 allele was observed in 11% of spontaneous clearers compared to 17% of chronically
infected patients (OR= 0.59, 95% CI interval 0.35–0.99, P = 0.047). Carriage of this allele also tended to be observed more
frequently among patients with liver inflammation (19%) compared to those without inflammation (15%, OR= 1.38, 95% CI
interval 0.99–1.95, P = 0.06). The CCR5delta32 was not associated with sustained virological response (P = 0.6), fibrosis stage
(P = 0.8), or fibrosis progression rate (P = 0.4).
Conclusions: The CCR5delta32 allele appears to be associated with a decreased rate of spontaneous HCV eradication, but
not with hepatitis progression or response to antiviral therapy.
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Introduction
Hepatitis C virus (HCV) infects about 2.8% of the global
population [1] and is a major cause of chronic liver disease and
hepatic mortality worldwide [2,3]. Although the treatment of
HCV genotype 1, the most prevalent in western countries, still
relies on the use of pegylated interferon-alpha (IFN-alpha) and
ribavirin, with the addition of other direct-acting antivirals [2,3],
IFN-alpha-free regimens are currently being registered in several
countries and for all viral genotypes [4]. The advent of these well-
tolerated, highly efficacious drugs will revolutionize HCV screen-
ing strategies and the consequent assessment of treatment needs.
The factors influencing liver fibrosis progression and response to
antivirals are complex and involve host, viral and environmental
factors. Multiple host genetic polymorphisms affecting HCV-
related liver inflammation, fibrosis progression and response to
therapy have been reported encompassing a broad variety of
genes, including IFNL3, associated with spontaneous and
treatment-induced HCV clearance [5–9], as well as several genes
recently associated with accelerated fibrosis progression rate
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[10,11]. The clinical implications of these findings are consider-
able, since the future management of hepatitis C – especially the
prioritization in costly treatment allocation – may increasingly
depend on patient profiling, including host genetic polymor-
phisms.
The chemokine receptor CCR5 was identified as one of the
major coreceptors for the human immunodeficiency virus-1 (HIV-
1). A 32-bp deletion in exon 4 of CCR5 (CCR5delta32) results in a
non-functioning receptor that is trapped in the endoplasmic
reticulum and therefore not expressed at the cell surface. This
deletion occurs –at the homozygous state– in 0.7–1.6% of the
Caucasian population: homozygous carriers are resistant to M-
tropic strains of HIV-1 and a number of new anti-HIV drugs,
called CCR5 receptor antagonists, have been designed to interfere
with the interaction between CCR5 and HIV. CCR5 is expressed
on many cell types, including Th1 cells [12] and hepatic stellate
cells (HSCs) [13,14], suggesting that this receptor may be
important in viral clearance, response to therapy and fibrogenesis
in chronic hepatitis C. Th1 response and increased CD8 T cell
response via IFN-gamma production was associated with viral
clearance and spontaneous recovery from acute HCV infection
[15]. In contrast, the development of persistent chronic HCV
infection has been correlated with an impaired Th1 response [15–
17]. According to the hypothesis that CCR5 promotes the
recruitment of Th1-expressing cells into the liver to mediate the
clearance of HCV-infected hepatocytes, reduced expression of
CCR5 should be associated with viral persistence. In case of
chronic HCV infection we expect that the CCR5 deletion should
decrease liver inflammation and fibrosis. CCR5 is also recognized
as an important mediator of pro-fibrogenic signalling in HSCs.
Bruno et al [14] have shown that the HIV envelope glycoprotein
gp120 directly acts on HSCs through the use of the CCR5
receptor, and one large study found a significant association
between CCR5delta32 and reduced fibrosis [18]. However, the
observational studies about CCR5 expression, spontaneous
clearance, inflammatory activity during chronic HCV infection
and the viral response to pegylated IFN-alpha and RBV treatment
have provided controversial and conflicting results.
The aim of our study was to clarify the role of the CCR5delta32
allele in HCV-related outcomes, by performing comprehensive
genotyping of CCR5 in a large and diverse population of anti-
HCV-positive persons and by correlating findings with the degree
of liver inflammation, fibrosis stage, fibrosis progression rate,
steatosis, HCV spontaneous clearance and response to IFN-alpha-
based therapy. We also hypothesized that the results of this study
may open new perspectives in the treatment of HCV-HIV
coinfected patients with CCR5 antagonists such as maraviroc, a
currently available anti-HIV drug.
Materials and Methods
Study patients
Patients were included from the Swiss Hepatitis C Cohort Study
(SCCS), a multicenter study enrolling anti-HCV-positive persons
at eight major Swiss hospitals since 2000 [19,20] and from an
Italian cohort (IC) contributed by the Liver Unit at the ‘‘Casa
Sollievo della Sofferenza’’, San Giovanni Rotondo, Italy. The
study was reviewed and approved by the ethics committee of the
Department of Medicine, Geneva University Hospitals, Geneva,
Switzerland (protocol 2000-28) and the ethics comittee of IRCSS
Casa Sollievo della Sofferenza, San Giovanni Rotondo. Only
patients with available DNA and written informed consent for
genetic studies were enrolled. Among 3,775 adult anti-HCV
positive patients included in the SCCS up to March 2013, 1,332
had genomic DNA available which could be isolated and analyzed
by PCR to identify CCR5delta32. An additional 118 adult anti-
HCV positive patients were contributed from the IC, totalling
1,450 patients for the present study. We included both persons
with spontaneous HCV clearance (defined as presence of anti-
HCV but undetectable HCV RNA without history of previous
antiviral treatment) and patients with chronic infection with HCV
genotypes 1, 2, 3, or 4, treated or not with pegylated IFN-alpha
and ribavirin. Demographic and clinical features (including age,
gender, body mass index (BMI), risk factors for HCV acquisition,
HCV genotypes, IFNL3 rs12979860 polymorphisms, alcohol
consumption, type 2 diabetes, markers of infection with HIV and
hepatitis B virus, HCV RNA, transaminase levels, liver histology,
and data on HCV treatment) were extracted from clinical
databases. A sustained virological response (SVR) to anti-HCV
therapy was defined as an undetectable HCV RNA in serum 24
weeks after treatment termination. Liver specimens were formalin-
fixed and paraffin-embedded for histological evaluation and
analyzed by experienced pathologists. Necroinflammatory activity
and fibrosis were scored according to the Metavir scoring system
[21]. Significant activity and fibrosis were defined as Metavir
scores $A2 and $F2, respectively. Severe activity and fibrosis
corresponded to Metavir scores of $A3 and $F3. Fibrosis
progression rate was calculated in 921 patients with an estimated
date of infection, as previously described [20]. Steatosis was
defined as present ($5% of hepatocytes) or absent.
CCR5 genotyping
The presence of the CCR5delta32 deletion was assessed by
PCR on DNA extracted from peripheral blood mononuclear cells
drawn from all patients and processed by standard protocols. The
following primers were used to amplify 274-bp (wild type) and
242-bp (delta32 deletion) fragments of CCR5, respectively: sense,
59- TTTACCAGATCTCAAAAAGAAG -39 and antisense, 59-
GGAGAAGGACAATGTTGTAGG -39. The following condi-
tions for the PCR reactions were used: 5 min at 95uC, 1 min at
95uC, 1 min at 57uC, 1 min at 72uC (30 cycles), and finally 5 min
at 72uC. PCR products were analyzed on a 3% agarose gel.
Statistical analyses
Statistical analyses were performed in Stata 12Software
(StataCorp LP, College Station, Texas, USA). The association
between CCR5delta32 and the different phenotypes (spontaneous
clearance [both cohorts] and clinical and histological outcomes
[SCCS dataset only] including hepatic inflammation, fibrosis,
fibrosis progression rate and response to therapy) were assessed in
univariate and multivariate regression models. Due to the relative
rare allele frequency of CCR5delta32, the associations were
assumed for an dominant mode of inheritance (patients hetero-
zygous and homozygous for the rare alleles were compared to the
other). Fibrosis progression rate was dichotomized using the
median value, i.e. 0.08 fibrosis Metavir unit per year. Multivariate
stepwise regression models (P,0.2) were used to determine the
independent risk factors from the predicted variables.
Results
Patient population
The 1,450 patients’ features are summarized in Table 1. Most
patients were males (62%), all were Caucasians, and 160 (11%)
were spontaneous clearers. The minor allele frequencies of
CCR5delta32 and IFNL3 rs12979860 were 8.6% and 36.8%,
respectively. The frequency of CCR5delta32 was similar in
patients with or without HIV coinfection (Fischer test, P = 0.87).
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The most frequently reported risk factor among chronically
infected patients was the use of intravenous drugs (46%). Alcohol
consumption .40 g/day in the 5 past years was reported in 21%
of chronically infected patients, HIV coinfection in 8% and
diabetes in 6%. Of note, none of the HIV-infected patients were
carriers of the CCR5delta32 allele at the homozygote state.
Liver fibrosis was assessed at histology in 1,017 patients before
any anti-HCV treatment susceptible to modify Metavir scores: 921
had an estimated infection date, making them assessable for the
fibrosis progression rate estimation. Significant ($A2) and severe
($A3) inflammation were present in 58 and 17% of the patients,
respectively, while significant ($F2) and severe fibrosis ($F3) were
present in 56 and 27% of the patients, respectively, 16% of them
having cirrhosis (F4). As expected, the median fibrosis progression
rate was not normally distributed, with a median of 0.08
(interquartile range = 0.093), and a mean of 0.108 (range 0-1)
fibrosis units per year. Six hundred ninety three patients were
assessable for response to treatment with pegylated IFN-alpha and
ribavirin, and 60% of them reached SVR.
Table 1. Patient characteristics.
Chronic infection Spontaneous clearance
N=1290 N=160
Male gender1 0.62 0.54
Caucasian ethnicity 1.0 1.0
Median age at infection (IQR)2 20 (9) 38 (19)
HCV reported risks
Drug use 0.46 0.24
Invasive procedures/needle stick 0.24 0.22
Transfusion 0.18 0.29
Other/Unknown 0.13 0.24
HCV genotype3
1 0.49 NA
2 0.09 NA
3 0.28 NA
4 0.10 NA
Alcohol consumption4
.40 g/d for $5 years 0.21 NA
Diabetes 0.06 NA
Median BMI (kg/m2, IQR)5 24 (5) NA
HIV+6 0.08 NA
Response to pegylated IFN-alpha and ribavirin therapy7 0.60 NA
Liver histological features
Histological activity8
A0 0.42 NA
A1-A3 0.58 NA
A0-A1 0.83 NA
A2-A3 0.17 NA
Fibrosis stage (Metavir)9
F0-F1 0.44 NA
F2-F4 0.56 NA
Steatosis10 0.63 NA
Numbers are the proportion of patients with the indicated feature.
1Gender was missing in 1 patient with spontaneous clearance.
2Age at estimated date of infection for patients with chronic infection, at cohort entry for those with spontaneous clearance (missing in 2 patients).
3HCV genotype was missing in most patients with spontaneous clearance and in 46 chronically infected patients.
4Alcohol consumption data before treatment was missing in 18 patients.
5BMI treatment was missing in 215 patients.
6HIV serology was missing in 214 patients.
7Response treatment was assessable in 693 patients.
8Histological activity before treatment was missing in 279 patients.
9Fibrosis stage before treatment was missing in 273 patients.
10Steatosis data before treatment were missing in 155 patients.
doi:10.1371/journal.pone.0106424.t001
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Chronic vs. spontaneously cleared HCV infection
Carriage of CCR5delta32 was observed in 11% of spontaneous
clearers compared to 17% of chronically infected patients
(OR = 0.59, 95% CI interval 0.35–0.99, P = 0.047). The associa-
tion between CCR5 deletion and HCV spontaneous clearance was
similar albeit less significant when patients with positive HIV
serology were removed (P = 0.09) (Table 2). The association was
slightly less significant in a multivariate model (OR = 0.60, 95% CI
0.35–0.99, P = 0.07), after adjustment for relevant covariates,
including IFNL3 rs12979860 (OR = 0.35, 95% CI 0.24–0.49,
P = 2.8E-9), male sex (OR = 0.76, 95% CI 0.53–1.07, P = 0.12),
and infection by invasive procedure or needle stick (OR = 1.61,
95% CI 0.98–2.63, P,0.001), blood transfusion (OR = 2.91, 95%
CI 1.81–4.66, P = 0.06), or through another risk (OR = 3.55, 95%
CI 2.17–5.81, P,0.001), compared to drug use (Table 3). Yet, the
number of patients in the multivariate analysis was smaller
(N = 1400), due to the fact that certain patients had missing
covariates.
Other phenotypes
Carriage of the CCR5delta32 allele was not associated with
SVR (P = 0.6), fibrosis stage (P = 0.4), fibrosis progression rate
(P = 0.5), or steatosis (P = 0.8). However, it tended to be observed
more frequently among patients with liver inflammation (19%)
compared to those without inflammation (15%, OR = 1.38, 95%
CI interval 0.99–1.95, P = 0.06) (Table 2). However, the trend was
weaker in a multivariate model (OR = 1.35, 95% CI 0.91–2.01,
P = 0.14), after adjustment for IFNL3 rs12979860 (P = 0.08), age
at infection (P = 0.008) and steatosis (P,0.001) (Table 4).
Discussion
Our study is based on the largest cohort of Caucasian anti-HCV
positive patients with the most exhaustive determination of
CCR5delta32 and other variables potentially associated with
HCV clearance. With 15.1% of them being heterozygous and
1.1% homozygous for CCR5delta32, it is representative of the
expected distribution of this allele in a Caucasian population.
The aim of our study was to clarify the potential role of
CCR5delta32 in the outcome of HCV infection. With the new
perspective of treatment of HCV-HIV co-infected patients with
CCR5 antagonists such as maraviroc, a current anti-HIV therapy,
this is an important question to debate in terms of safety and
efficacy.
Firstly, we analysed the relationship between CCR5delta32 and
HCV spontaneous clearance. By univariate analysis, HCV
clearance was negatively associated with homo- or heterozygous
CCR5delta32, polymorphisms at IFNL3 rs12979860, male
gender, and positively associated with HCV acquisition through
intravenous drug use, invasive procedures and especially by blood
transfusion. Considering the possibility of some bias induced by
co-infection with HIV and by the interaction between HIV and
CCR5, we performed the same analysis after exclusion of co-
infected patients: the association between CCR5 deletion and
HCV spontaneous clearance was similar albeit less significant
Table 2. Association of CCR5delta32 with different HCV-related endpoints.
CCR5delta321
Variable absent % present % OR (95% CI) P
Spontaneous clearance2
No 1073 0.83 217 0.17 Reference
Yes 143 0.89 17 0.11 0.59 (0.35–0.99) 0.047
Sustained virological response
No 228 0.83 47 0.17 Reference
Yes 340 0.81 78 0.19 1.11 (0.75–1.66) 0.6
Fibrosis stage (Metavir)
F0-F1 372 0.84 71 0.16 Reference
F2-F4 472 0.82 104 0.18 1.15 (0.83–1.60) 0.4
Fibrosis progression rate
,0.08 378 0.82 82 0.18 Reference
$0.08 388 0.84 74 0.16 0.88 (0.62–1.24) 0.5
Inflammation
A0 359 0.86 61 0.15 Reference
A1-A3 480 0.81 114 0.19 1.38 (0.99–1.95) 0.06
A0-A1 700 0.83 139 0.17 Reference
A2-A3 137 0.79 37 0.21 1.36 (0.91–2.04) 0.1
Steatosis
absent 252 0.83 52 0.17 Reference
present 538 0.82 115 0.18 1.04 (0.72–1.49) 0.8
1Due to the relative low CCR5delta32 allele frequency (8.6%), data are presented for the dominant mode of inheritance.
2The number patients carrying 0, 1 or 2 copies of CCR5delta32 were 1073, 202 and 15 for patients with chronic infection and 143, 16 and 1 for spontaneous clearers. The
associations were also tested by using the additive (OR= 0.61, 95% CI 0.38–1.00, P = 0.05) and recessive (OR = 0.53, 95% CI 0.07–4.07, P = 0.5) modes of inheritance. The
association was similar albeit less significant when patients with positive HIV serology were removed (OR = 0.63, 95% CI 0.36–1.08, P = 0.09).
doi:10.1371/journal.pone.0106424.t002
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when patients with positive HIV serology were removed (P = 0.09).
The association between the CCR5delta32 and HCV clearance
barely lost statistical significance after adjustment for IFNL3
rs12979860 and male gender. This observation matches the
hypothesis that a reduced expression of CCR5 at the cell surface
would impair the recruitment of Th1-expressing cells into the liver
to mediate the clearance of HCV-infected hepatocytes, promoting
persistence of HCV infection [15–17].
The currently available data on the frequency of CCR5delta32
in HCV-infected vs -cleared individuals are not unequivocal. Our
results, based on a large cohort of 1,450 patients, are in conflict
with some smaller studies. A recent Egyptian study enrolling 190
HCV-infected patients, mainly with HCV genotype 4 and
coinfected with Schistosoma mansoni, showed a highly significant
positive association between spontaneous HCV clearance and
CCR5delta32 [22]. In another series of 283 female patients with
HCV genotype 1, Goulding et al. showed an association between
CCR5delta32 and an increased rate of spontaneous clearance
[23]. In more recent work, on the other hand, Nattermann et al.
[24] evaluated a cohort of 396 Caucasian female patients infected
with a single source of HCV genotype 1 and showed that both
IFNL3 rs1297860 CT/TT and CCR5delta32 variants were
independently associated with a decreased rate of spontaneous
HCV clearance. An increased prevalence of CCR5delta32
homozygosity was reported in haemophilic patients with chronic
HCV infection, with or without HIV coinfection, compared with
the general population [25], suggesting that CCR5delta32 may
favor HCV persistence. Thus, considering all these data together,
if on the one hand patients with HCV infection and CCR5delta32
may be protected against HIV, on the other hand the functional
blockade of CCR5 with drugs (e.g. maraviroc) in HIV-infected
people may be associated with increased risk of progression to
persistence in case of primary HCV infection.
Based on the assumption that a decreased expression of CCR5
impairs the Th1 response, we assessed whether the CCR5delta32
allele may influence the response to pegylated IFN-alpha and
ribavirin therapy. The efficacy of IFN-alpha has been attributed to
its ability to partially up-regulate CCR5 expression on T cells [26].
Our results show that this CCR5 polymorphism did not play any
significant role in the anti-HCV treatment response, while at the
same time confirming the very well known role played by severe
fibrosis, older age, higher pretreatment HCV RNA, genotype 2
and 3 and IFNL3/4 genetic polymorphisms. As already known,
the latter are currently the strongest host genetic markers to
Table 3. Factors associated with spontaneous HCV clearance.
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
CCR5delta32 (dominant) 0.59 (0.35–0.99) 0.047 0.60 (0.35–1.04) 0.07
IFNL3 rs12979860 (dominant) 0.36 (0.27–0.51) 5.9E-9 0.35 (0.24–0.49) 2.8E-09
Male gender 0.71 (0.51–0.99) 0.04 0.76 (0.53–1.07) 0.12
Risk factors
Drug use Reference Reference
Invasive procedure, needle stick 1.77 (1.10–2.86) 0.02 1.61 (0.98–2.63) ,0.001
Blood transfusion 3.04 (1.92–4.80) ,0.001 2.91 (1.81–4.66) 0.06
Other/missing 3.47 (2.14–5.61) ,0.001 3.55 (2.17–5.81) ,0.001
doi:10.1371/journal.pone.0106424.t003
Table 4. Factors associated with liver histological activity.
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
CCR5delta32 (dominant) 1.38 (0.99–1.95) 0.06 1.35 (0.91–2.01) 0.14
IFNL3 rs12979860 (dominant) 0.76 (0.58–0.99) 0.04 0.76 (0.55–1.03) 0.08
Male gender 1.43 (1.11–1.85) 0.006
Age at infection (continuous) 1.02 (1.01–1.04) ,0.001 1.02 (1.01–1.04) 0.008
Log HCV RNA IU/ml(continuous) 0.86 (0.76–0.98) 0.02
Steatosis 2.33 (1.76–3.10) ,0.001 2.36 (1.73–3.22) ,0.001
HCV genotype
1 Reference
2 1.47 (0.93–2.33) 0.01
3 1.32 (0.98–1.77) 0.07
4 0.82 (0.53–1.25) 0.4
Other/missing 1.03 (0.35–3.01) 1.0
Note: stepwise logistic regression (cutoff P = 0.15).
doi:10.1371/journal.pone.0106424.t004
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predict IFN-alpha-based treatment-induced HCV clearance, and,
as demonstrated in a recent and large serie of 813 Caucasian
patients with chronic hepatitis C genotype 1 [27], CCR5delta32
did not improve prediction of SVR in the context of the IFNL3
polymorphisms. These results match those of previous, smaller
series [28–31], but appear in conflict with those of an early study
which had identified CCR5delta32 carriage as an independent
negative predictor for the end of treatment virological response to
the less potent IFN-alpha monotherapy [30]. This suggests that the
role of CCR5delta32 may no longer be relevant in predicting the
treatment-induced clearance of HCV when more powerful
regimens are used.
If CCR5 is partly responsible for the recruitment of Th1 cells, a
decreased expression of CCR5 should result in milder inflamma-
tion, as showed by Hellier and Goulding [18,22].
Immunohistochemical analysis of liver biopsies of patients
chronically infected with HCV genotype 1 showed a significant
positive correlation between the percentage of intrahepatic CCR5
high-expressing CD8+ cells and both porto-periportal and lobular
activity [32].
Other studies [31,33] reported a lack of correlation between
CCR5 deletion and liver inflammation. Our data show a trend
towards increased inflammation in the presence of CCR5delta32.
Considering the relationship between CCR5 and TH1 cells, this
observation is difficult to explain. However, it is known that CCR5
is not the only chemokine receptor involved in Th1 response
[32,34]: also CXCR3 and CXCR6 play a major role in recruiting
cytotoxic T cells and secreting type 1 cytokines in the liver, and it
is likely that, in case of the CCR5 deletion, other chemokine
receptors may contribute to the inflammatory response. The
positive correlation between CCR5delta32 and inflammation was
found only when considering A0 vs A1-3 but disappeared when
considering A0-1 vs A2-3, suggesting that CCR5 deletion probably
does not play any role in significant inflammation.
Finally, we aimed to study fibrosis and fibrosis progression rate
as a function of CCR5 expression. CCR5 is recognised as an
important mediator of pro-fibrogenic signalling in HSCs and the
CCR5 deletion should protect against fibrosis progression.
Recently, Bruno et al. [14] demonstrated that the HIV envelope
glycoprotein gp120 directly acts on HSCs through the use of the
CCR5 receptor. The link between homozygous CCR5delta32 and
HCV fibrogenesis has been analysed in several studies. CCR5-
deficient mice displayed reduced hepatic fibrosis and macrophage
infiltration [35]. Hellier et al [18] evaluated a cohort of 623 HCV-
infected patients and found a significant association between the
CCR5delta32 homozygous genotype and reduced portal inflam-
mation and milder fibrosis.
Most of the other studies failed to demonstrate any significant
relationship between the CCR5delta32 mutation and the course of
chronic hepatitis C [22,28,31,33]. Our work did not identify any
association between CCR5delta32 and liver grading or staging.
When considering only CCR5delta32 homozygous patients,
severe and significant fibrosis were found in 8 and 25% of
patients, respectively, vs 28 and 54% in patients with the wild type
CCR5. However the number of homozygous patients was too
small to reach any statistical significance. As already suggested by
several studies [33,36–39], the use of CCR5 antagonist such as
maraviroc, should be safe in patients with HIV and chronic
hepatitis C, at least as far as liver histology and the efficacy of anti-
HCV treatment are concerned. A pilot clinical trial suggested that
maraviroc may even reduce the liver fibrosis progression in HIV-
HCV coinfected patients [39]. Our data do not support a potential
antifibrotic effect of CCR5delta32, perhaps due to the small
number of CCR5delta32 homozygous patients and also to the
prevailing effect of other pro-fibrogenic variables. Only a large
randomized prospective study might assess this effect of the CCR5
antagonist, if any. An anti-HIV investigational drug, the
cenicriviroc, being both a CCR5 and CCR2 inhibitor, demon-
strated good antiviral activity and tolerability in a Phase 2 clinical
trial. Whether this new anti-inflammatory activity on the top of a
CCR5 blockage could be efficient to decrease fibrosis rate in
HCV- (co-) infected patients remains to be proven.
In conclusion, our results, based on a large cohort of 1,450
HCV-infected patients, genotyped for the CCR5delta32 allele and
representative of the distribution of this allele in a Caucasian
population, showed that that both IFNL3 rs1297860 CT/TT
and CCR5delta32 alleles were associated with a decreased
spontaneous HCV clearance, although the multivariate analysis
barely failed to reach statistical significance for the latter. The
CCR5delta32 deletion was not associated with fibrosis, fibrosis
progression rate, or therapy response. In the view that CCR5
inhibitors are now available for HIV treatment, this is an
important observation: our data suggest that these drugs could
impair the odds of spontaneous clearance of acute HCV infection
in HIV-infected patients on active treatment with anti-CCR5.
However drug-induced impairment of CCR5 signaling should
neither modify HCV histological outcomes nor impair the efficacy
of anti-HCV therapy.
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